What is the Work Group's recommendation on vitamin D supplementation related to statin-induced myopathy?
The Work Group was unable to make a recommendation on vitamin D supplementation. The confidence in the quality of the two available cohort studies was very low based on a small number of patients and different protocols for vitamin D supplementation. For almost all patients, there are no significant harms associated with the trial of a different statin or implementation of intermittent dosing, and there is a potential benefit of continuing treatment. Because most agents in the class are available in generic formulations, it is unlikely that switching statins will add a substantial financial burden. With proper education, it is expected that most patients will be amenable to a change in statin or an intermittent dosing schedule.